Temat: anticoagulation - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19
Autorzy:: Czarnecka-Czapczyńska, Magdalena
Bartusik-Aebisher, Dorota
Krupka-Olek, Magdalena
Aebisher, David
Cieślar, Grzegorz
Latos, Wojciech
Kawczyk-Krupka, Aleksandra
Tematy:: anticoagulation
coagulation abnormalities
COVID-19; Pokaż więcej
Wydawca:: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Powiązania:: https://bibliotekanauki.pl/articles/2040166.pdf Link otwiera się w nowym oknie
Opis:: Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2). Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19. Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19. Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts. Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Skocz do pozycji: 2.

Tytuł:: Prevalence of thromboembolic (VTE) events in a South London District hospital: a retrospective study
Autorzy:: Woodward-Stammers, E.
Ponto, M.
Tematy:: Thromboembolism; hospitalised patients; prevention
anticoagulation; Pokaż więcej
Wydawca:: Uniwersytet Medyczny w Białymstoku
Powiązania:: https://bibliotekanauki.pl/articles/1918927.pdf Link otwiera się w nowym oknie
Opis:: Introduction: Venous thromboembolism (VTE) has been defined by many professionals as the term to describe deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a condition where a thrombus (blood clot) forms in the deep veins usually the lower limbs. DVT can often propagate to the lungs causing PE which can result in significant health complications including instant fatality. The disease occurs in 1 in 20 people in the United Kingdom (UK) at some point during their life time Purpose: To investigate the prevalence of VTE in a South London hospital over a period of 3 years. The objectives of the study were to explore the characteristics of VTE by examining potential correlations with demographic variables of gender, age and ethnicity. Another objective was to distinguish between hospital-associated VTE and community-associated VTE and to identify prevalent types of VTE. Materials and methods: This was a retrospective, quantitative study using convenience sampling. Records of 1728 patients diagnosed with VTE between 1st January 2014 and 31st December 2017 were selected. The data was collected using a clinical computer system to gather patient demographics and identify whether the episode of VTE was related to a hospital admission. Data was analysed using SPSS 23 in order to create descriptive statistics. Spearman’s correlation test was carried out to assess potential correlations between incidences of VTE with age. Jonckheere trend tests were used to assess the significance of trends. Results: The highest incidence of VTE was among the white population n=1470 (85.1%). The average age of the participants in the study was 66.96 years (standard deviation 17.8), There was a positive correlation between incidence of VTE and age (r=0.078, p=0.001). There were more females diagnosed with VTE, n=895 (51.8%) than males n=833 (48.2%). This trend was significant at 0.05. Conclusion: VTE is a concern for the general population and is a major health problem affecting 99 people per 100,000 of the population each year. This common disease is prevalent among all individuals irrespective of age, ethnicity or gender and is not always related to episodes of hospitalization. Further research is needed to examine risk factors and rates of VTE and to establish whether individual events are triggered by transient or acquired influences and causal relationships
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Skocz do pozycji: 3.

Tytuł:: Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke
Autorzy:: Plens, Krzysztof
Gissel, Matthew
Kusak, Piotr
Butenas, Saulius
Czarnecka, Danuta
Undas, Anetta
Opis:: Introduction: Previously, we have demonstrated that significant proportions of patients with various cardiovascular diseases have active tissue factor and active factor XIa in their plasma. In the current study, we evaluated active tissue factor and active factors (F)XI and FIX in plasma from patients with atrial fibrillation. Material and methods: In 110 consecutive patients with permanent atrial fibrillation receiving warfarin, we determined active tissue factor, together with plasma FIXa and FXIa, using clotting assays by measuring the response to inhibitory monoclonal antibodies. Results: Sixteen (14.5%) patients had detectable active tissue factor and active FXIa, including 11 subjects with both factors, while FIXa was observed in 28 (25.7%) patients. The three positive groups did not differ from the patients without these factors with regard to demographic and clinical characteristics. Von Willebrand factor was higher in the active tissue factor-positive group (p < 0.0001) and FXIa-positive group (p = 0.0037). Individuals positive for active tissue factor and FXIa had higher plasma interleukin-6 levels (p = 0.0014 and 0.0322, respectively). The presence of active tissue factor, FXIa and FIXa in anticoagulated patients with permanent atrial fibrillation correlated with elevated von Willebrand factor and interleukin-6. During a 3-year follow-up, ischemic stroke (n = 12, 10.9%) occurred more commonly among atrial fibrillation patients who had circulating TF (p = 0.002) or FXIa (p = 0.013). Conclusions: These data suggest that circulating active coagulation factors, in particular TF and FXIa, can be detected despite oral anticoagulation in a significant proportion of patients with atrial fibrillation, and could represent novel markers of persistent prothrombotic alterations predisposing to ischemic stroke.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 4.

Tytuł:: Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry
Autorzy:: Tokarek, Tomasz
Gawałko, Monika
Wójcik, Maciej
Gorczyca, Iwona
Rajtar-Salwa, Renata
Maciorowska, Małgorzata
Bakuła-Ostalska, Elwira
Jelonek, Olga
Wojewódzki, Michał
Błaszczyk, Robert
Szpotowicz, Anan
Tomaszuk-Kazberuk, Anna
Bil, Jacek
Szyszkowska, Anna
Budnik, Monika
Uziębło-Życzkowska, Beata
Mamcarz, Artur
Kapłon-Cieślicka, Agnieszka
Wełnicki, Marcin
Bednarski, Janusz
Krzciuk, Małgorzata
Opis:: Background: We aimed to assess characteristics and treatment of AF patients with and without heart failure (HF). Methods: The prospective, observational Polish Atrial Fibrillation (POL-AF) Registry included consecutive patients with AF hospitalized in 10 Polish cardiology centers in 2019–2020. Results: Among 3999 AF patients, 2822 (71%) had HF (AF/HF group). Half of AF/HF patients had preserved ejection fraction (HFpEF). Compared to patients without HF (AF/non–HF), AF/HF patients were older, more often male, more often had permanent AF, and had more comorbidities. Of AF/HF patients, 98% had class I indications to oral anticoagulation (OAC). Still, 16% of patients were not treated with OAC at hospital admission, and 9%—at discharge (regardless of the presence of HF and its subtypes). Of patients not receiving OAC upon admission, 61% were prescribed OAC (most often apixaban) at discharge. AF/non–HF patients more often converted from AF at admission to sinus rhythm at discharge compared to AF/HF patients (55% vs. 30%), despite cardioversion performed as often in both groups. Class I antiarrhythmics were more often prescribed in AF/non–HF than in AF/HF group (13% vs. 8%), but still as many as 15% of HFpEF patients received them. Conclusions: Over 70% of hospitalized AF patients have coexisting HF. A significant number of AF patients does not receive the recommended OAC.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 5.

Autorzy:: Potpara, Tatjana
Undas, Anetta
Drabik, Leszek
Opis:: Major bleeding (especially intracranial hemorrhage) is the most feared adverse event observed in patients with atrial fibrillation (AF) receiving oral anticoagulation. Clinical risk factor–based scores have modest ability to predict major or clinically relevant bleeds, and blood biomarkers are increasingly implemented to improve bleeding prognostication in patients with AF on life‑long anticoagulation. To improve the safety of anticoagulation in the era of non–vitamin K antagonist oral anticoagulants (NOACs, or direct oral anticoagulants [DOACs], including dabigatran, rivaroxaban, apixaban, and edoxaban), specific demographic, clinical, and laboratory variables should be considered. The current review summarizes practical challenges in the management of oral anticoagulation with emphasis on the risk assessment tools, elderly or underweight patients, cancer patients, impact of chronic kidney disease, liver cirrhosis, and thrombocytopenia in the context of bleeding risk in patients with AF.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 6.

Tytuł:: Plasma fibrin clot structure and thromboembolism : clinical implications
Autorzy:: Ząbczyk, Michał
Undas, Anetta
Opis:: Fibrin formed as a result of fibrinogen polymerization is the main protein component of a clot in a test tube and intravascular thrombi in vivo. Fibrin clot structure characterized by fiber diameter and pore size differs between healthy persons and those with thromboembolic diseases, in part due to the quality and quantity of fibrinogen and the magnitude of thrombin generation. A key measure of plasma clot structure is its permeability, reflected by the Darcy constant ($K_{s}$). Reduced $K_{s}$ is a typical feature of the prothrombotic fibrin clot phenotype, which is associated with faster formation of denser fibrin mesh, relatively resistant to lysis. Low $K_{s}$ has been reported in patients with prior or acute myocardial infarction (MI), stroke, or venous thromboembolism (encompassing deep vein thrombosis [DVT] and pulmonary embolism [PE]), as well as in those with prothrombotic conditions (eg, in several thrombophilic states) and in the presence of cardiovascular risk factors (eg, obesity). Antithrombotic and anticoagulant agents, along with statins, have been shown to increase $K_{s}$. Growing evidence indicates associations between the properties of plasma fibrin clots and morphology of intravascular thrombi in patients with MI. Recently, reduced $K_{s}$ has been shown to predict recurrent thromboembolic episodes in patients with a history of stroke, PE, DVT, and their serious complications, including postthrombotic syndrome and thromboembolic pulmonary hypertension. We discuss the current evidence for the significance of clot density measured in vitro as a prognostic marker in a number of clinical conditions associated with elevated thromboembolic risk.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 7.

Tytuł:: Współczesne poglądy na temat zastosowania heparyn drobnocząsteczkowych u chorych hemodializowanych
Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients
Autorzy:: Kowalczyk-Michałek, Martyna
Sułowicz, Władysław
Kraśniak, Andrzej
Drożdż, Maciej
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 8.

Tytuł:: Switching from acenocoumarol to warfarin in patients with unstable anticoagulation and its effect on anticoagulation control
Zmiana acenokumarolu na warfarynę u pacjentów o niestabilnej antykoagulacji i jej wpływ na kontrolę antykoagulacji
Autorzy:: Tracz, Wiesława
Cieśla‑Dul, Mariola
Żółciński, Marek
Undas, Anetta
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 9.

Tytuł:: Low bleeding acceptance is associated with increased death risk in patients with atrial fibrillation on oral anticoagulation
Autorzy:: Undas, Anetta
Natorska, Joanna
Konieczyńska, Małgorzata
Rusin, Gabriela
Malinowski, Krzysztof
Opis:: Bleeding is the most feared complication of anticoagulation. We sought to investigate whether the bleeding risk acceptance has a prognostic value during long-term follow-up in the era of direct oral anticoagulants (DOACs) among patients with atrial fibrillation (AF). We studied 167 consecutive AF outpatients [aged 68.8 SD 10.6 years; 141 (84.4%) on DOACs]. The bleeding acceptance was assessed based on the Bleeding Ratio defined as the declared maximum number of major bleedings that a patient would be willing to accept to prevent one major stroke. We recorded cerebrovascular ischemic events, major or clinically relevant non-major bleeds (CRNMB), and mortality. A median Bleeding Ratio was 4 (IQR 2–5). During follow-up of 946 patient-years, cerebrovascular ischemic events and/or death were observed in 28 patients (3.3%/ year) and major bleeding or CRNMB in 33 (4.6%/ year). The Bleeding Ratio was lower in patients who experienced cerebrovascular events or death (p = 0.004), but not bleeding. Patients with the Bleeding Ratio 0–3 were more often non-persistent to the OAC therapy, and more likely to have cerebrovascular event or die than those with higher bleeding acceptance (odds ratio 2.55; 0.95% CI 1.08–6.02) which was driven by the impact on mortality. The multiple Cox proportional hazards model showed that lower Bleeding Ratio, higher CHA$_{2}$DS$_{2}$-VASc score, and older age predicted cerebrovascular events or death during follow-up. AF patients who are willing to accept fewer serious bleedings to avoid major stroke during anticoagulation are more likely to experience death and/or cerebrovascular ischemic events, but not bleeding, what might be related to non-persistence.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 10.

Tytuł:: Thromboembolic recurrence frequency analysis in patients with deep vein thrombosis of lower extremities
Analiza częstości nawrotów zakrzepowo-zatorowych u pacjentów z zakrzepicą żył głębokich kończyn dolnych
Autorzy:: Vasyliuk, Sergyi
Atamaniuk, Vitaliia
Tematy:: anticoagulation
dabigatran etexilate
rivaroxaban
therapy
thrombosis
warfarin; Pokaż więcej
Wydawca:: Towarzystwo Pomocy Doraźnej
Powiązania:: https://bibliotekanauki.pl/articles/1033266.pdf Link otwiera się w nowym oknie
Opis:: INTRODUCTION: To estimate the incidence of thromboembolic recurrence in patients whose deep vein thrombosis (DVT) during the initial and long-term anticoagulation and after its termination was treated. MATERIAL AND METHODS: There were examined and treated 98 patients with deep vein thrombosis of various locations. Patients were observed during anticoagulation therapy (n=98) and after its perfor-mance (n=76) for between 7 and 120 months. Depending on the scheme of anticoagulation therapy patients were divided into three groups: the first group (n=32) received warfarin, the second group (n=34) – rivaroxaban, the third one (n=32) – dabigatran etexilate. RESULTS: In terms of initial and long-term anticoagulant therapy, regardless of the choice of treatment regimens, DVT recurrence or pulmonary embolism cases we have not observed. After the treatment, during the first year, recurrence of DVT was more frequent in patients of all groups. In patients of the first group their frequency was 15.38±7.08%, the second group – 8.7±5.88%, the third one – 3.7±3.63%, which did not differ significantly (p=0.33). In general, the overall observation period showed a recurrence rate among the patients of the first group was 10 cases, 4 cases in the second group, and three cases in the third group (p<0.05). There was no signifi-cant difference in the incidence of thrombosis recurrence was observed between patients taking rivaroxaban and dabigatran etexilate, whereas there was a significant difference between the first and third groups (p<0.05). CONCLUSIONS: Long-term anticoagulation with warfarin is the least predictable as for the risk of re-currence of DVT (p<0.05), when the application of Rivaroxaban and dabigatran etexilate showed no significant difference in the incidence of DVT recurrence. Patients with provoking persistent risk factors and non-triggering factors require continued anticoagulation therapy indefinitely, or until this risk factor has been eliminated.
WSTĘP: Oszacowanie częstości nawrotów zakrzepowo-zatorowych u pacjentów z zakrzepicą żył głębokich (eng. deep vein thrombosis - DVT) w trakcie wstępnego i długoterminowego leczenia przeciwzakrzepowego oraz po jego zakończeniu. MATERIAŁ I METODY: Przebadano i leczono 98 pacjentów z zakrzepicą żył głębokich w różnych lokalizacjach. Pacjentów obserwowano podczas leczenia przeciwzakrzepowego (n = 98) i po jego wykonaniu (n = 76) przez okres od 7 do 120 miesięcy. W zależności od schematu leczenia przeciwzakrzepowego pacjentów podzielono na trzy grupy: pierwsza grupa (n = 32) otrzymała warfarynę, druga grupa (n = 34) - rywaroksaban, trzecia (n = 32) - eteksylan dabigatranu. WYNIKI: Pod względem początkowej i długotrwałej terapii przeciwzakrzepowej, niezależnie od wyboru schematów leczenia, nie zaobserwowano nawrotów DVT lub przypadków zatorowości płucnej. Po leczeniu w pierwszym roku nawrót DVT był częstszy u pacjentów ze wszystkich grup. U pacjentów w pierwszej grupie ich częstość wynosiła 15,38±7,08%, w drugiej grupie - 8,7±5,88%, w trzeciej - 3,7±3,63%, co nie różniło się istotnie (p = 0,33). Ogólnie rzecz biorąc, ogólny okres obserwacji wykazał, że odsetek nawrotów u pacjentów z pierwszej grupy wynosił 10 przypadków, 4 przypadki w drugiej grupie i trzy przypadki w trzeciej grupie (p <0,05). Nie stwierdzono istotnej różnicy w częstości nawrotów zakrzepicy między pacjentami przyjmującymi rywaroksaban i eteksylan dabigatranu, podczas gdy istniała znacząca różnica między pierwszą a trzecią grupą (p <0,05). WNIOSKI: Długoterminowe leczenie przeciwzakrzepowe warfaryną jest najmniej przewidywalne, jeśli chodzi o ryzyko nawrotu DVT (p <0,05), gdy stosowanie rywaroksabanu i eteksylanu dabigatranu nie wykazało istotnych różnic w częstości nawrotów DVT. Pacjenci z prowokującymi uporczywymi czynnikami ryzyka wymagają ciągłej terapii przeciwzakrzepowej przez czas nieokreślony lub do momentu wyeliminowania tego czynnika ryzyka.
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Informacja

Wyszukujesz frazę "anticoagulation" wg kryterium: Temat